Biotech Values

[ghmm]

FGEN:

The one thing I wonder about and perhaps explains why liver fibrosis (NASH) is slow tracted is IP. IPF, DMD and their subset of PC would all qualify as Orphan indications so they get the 7/10 exclusivity. Some of the oncology indications I'm not so sure about.

I still think they fit well in GILD's sweet spot. "Derisked" (as much as is possible for IPF) Phase 2 asset ready for P3 for them to put input. Seems actually a lot like Filgotinib at stage and potential for multiple indications.

At least its pretty clear Neff will partner and it sounded like sooner rather than later too.
If the data have no warts and look as good as they seem I'd imagine Roche and BI should be interested. BMY in addition to the oncology angle have done several fibrosis deals so imagine they should have interest too.